About the Company
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide™ platform is a new approach to precise gene insertion that harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVy™ capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The company is based in Lexington, MA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LOGC News
A Gaithersburg firm just secured $35M from a longtime backer
Immunomic Therapeutics Inc., a cancer therapy company based in Rockville, similarly has raised multiple batches of funding in ...
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends Suggest A USD 2,517 Million Valuation By 2032
According to Market.us, the global market size for alpha-1 antitrypsin deficiency augmentation therapy is projected to reach approximately USD 2,517 million by 2032, up from USD 1,413 million in 2022.
Aligos Therapeutics describes new prodrugs to treat hepatitis B and D virus infections
Aligos Therapeutics Inc. has identified prodrugs reported to be useful for the treatment of hepatitis B and hepatitis D viral infections.
ContextLogic Inc (WISH) Shares Rise Despite Market Challenges
Based on ContextLogic Inc (WISH), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -26.23. The debt to equity ratio ...
Loading the latest forecasts...